No Data
Hehui China (603122.SH): is closely collaborating with technical partners to conduct in-depth research on the DeepSeek large model and the feasibility of integrating it into our products.
On April 16, Glonghui reported that Hefei China (603122.SH) stated on the interactive platform that there is an understanding of concerns regarding technology choices. During last year's R&D process, DeepSeek had not been launched, and the company's clinical diagnosis AI-assisted system had already begun to be constructed and deployed when it became available for open use, so DeepSeek was not adopted as the underlying foundational large model. However, there is a commitment to continuously improve the technical level and market competitiveness of the products. Currently, the company is closely cooperating with technology partners to thoroughly research DeepSeek's large model and the feasibility of integrating it into our products.
Hefu China Revenue Report for January-March 2025
He Zhong China (603122.SH): From January to March, consolidated revenue decreased by 26.35% year-on-year.
On April 10, Gelonghui reported that Heji China (603122.SH) announced that the consolidated revenue from January to March 2025 was 175.7358 million yuan, a decrease of 26.35% compared to the same period last year. The consolidated revenue from January to February 2025 fell by 27.08% compared to the same period last year, with the decline narrowing by 0.73%, indicating continued improvement in revenue.
Cowealth Medical ChinaLtd's (SHSE:603122) Soft Earnings Don't Show The Whole Picture
Cowealth Medical China Applying for Up to 1.5 Billion Yuan Credit Line
Hefu China: Hefu China 2024 Annual Report Summary
Is Cowealth Medical China Co.,Ltd.'s (SHSE:603122) Stock On A Downtrend As A Result Of Its Poor Financials?